Catalyst Pharmaceuticals (CPRX) EPS (Weighted Average and Diluted) (2018 - 2025)
Historic EPS (Weighted Average and Diluted) for Catalyst Pharmaceuticals (CPRX) over the last 8 years, with Q3 2025 value amounting to $0.42.
- Catalyst Pharmaceuticals' EPS (Weighted Average and Diluted) rose 2000.0% to $0.42 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.72, marking a year-over-year increase of 4576.27%. This contributed to the annual value of $1.31 for FY2024, which is 10793.65% up from last year.
- Per Catalyst Pharmaceuticals' latest filing, its EPS (Weighted Average and Diluted) stood at $0.42 for Q3 2025, which was up 2000.0% from $0.41 recorded in Q2 2025.
- Over the past 5 years, Catalyst Pharmaceuticals' EPS (Weighted Average and Diluted) peaked at $0.45 during Q1 2025, and registered a low of -$0.29 during Q3 2023.
- For the 5-year period, Catalyst Pharmaceuticals' EPS (Weighted Average and Diluted) averaged around $0.23, with its median value being $0.23 (2022).
- In the last 5 years, Catalyst Pharmaceuticals' EPS (Weighted Average and Diluted) crashed by 24500.0% in 2023 and then skyrocketed by 22068.97% in 2024.
- Catalyst Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at $0.09 in 2021, then soared by 155.56% to $0.23 in 2022, then surged by 34.78% to $0.31 in 2023, then soared by 41.94% to $0.44 in 2024, then dropped by 4.55% to $0.42 in 2025.
- Its EPS (Weighted Average and Diluted) was $0.42 in Q3 2025, compared to $0.41 in Q2 2025 and $0.45 in Q1 2025.